UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus
Benzinga Newsdesk 3 days ago
FDANews
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among
- Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO
- Results demonstrate sustained disease control through extended follow-up among patients who achieved a complete response after treatment with JELMYTO
- No progression to high-grade disease was observed during extended follow-up